Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability.

Sanofi

Status and phase: Completed; Phase 3

Conditions: Hygiene

Treatments: Drug: Dermacyd Femina Pocket BR (Lactic Acid)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00794612

LACAC_L_04369

Details and patient eligibility

About

The purpose of this study is to prove the safety of the gynaecological formulation in normal conditions of use.

Enrollment: 30 patients

Sex: Female

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Integral skin test in the region;
• To use products of the same category;

Exclusion criteria

• Lactation or gestation;
• Use of anti-inflammatory, anti-histaminic or immunosuppressant drugs;
• Cutaneous disease (local or spread) in the evaluation area;
• Pathology which may cause immunity depression, such as HIV, diabetes;
• Endocrine pathology
• Solar exposure 15 days before evaluation;
• Treatment until four months before the selection.
• Allergic or atopic history to cosmetics products

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose: Supportive Care

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

1

Experimental group

Description:

Dermacyd Femina Pocket BR (Lactic Acid)

Treatment:

Drug: Dermacyd Femina Pocket BR (Lactic Acid)